Indivior PLC Directorate Change (5041L)

TIDMINDV

RNS Number : 5041L

Indivior PLC

03 October 2016

Indivior PLC (the "Company") - Directorate Change

Slough, UK, October 3, 2016 - Indivior PLC (LON: INDV) announces that Rupert Bondy, Senior Independent Director, stepped down from the Board with effect from September 30, 2016.

The Board confirms that Daniel Tassé has been appointed Senior Independent Director and a member of the Nomination & Governance Committee; he has stepped down from the Remuneration Committee. In addition, Lorna Parker has been appointed Chair of the Nomination & Governance Committee and Lizabeth Zlatkus has been appointed a member of the Remuneration Committee. These changes are effective immediately.

The Board will commence a search process for the appointment of a new Non-Executive Director.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its robust, global opioid dependence portfolio, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic diseases of addiction - including alcohol use disorders and cocaine intoxication. It also is pursuing a novel product candidate in a related mental health disorder, schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio is available in over 40 countries worldwide. Visit www.Indivior.com to learn more.

Forward-Looking Statements

This press release contains forward-looking statements. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may, " "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations.

Various factors may cause differences between Indivior's expectations and actual results, including: factors affecting sales of Indivior products and any future products; the outcome of research and development activities; decisions by regulatory authorities regarding the Indivior Group's drug applications; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group's products and product candidates; risks related to legal proceedings; the Indivior Group's ability to protect its patents and other intellectual property; the outcome of patent litigation relating to ongoing ANDA lawsuits; changes in governmental laws and regulations; issues related to the outsourcing of certain operational and staff functions to third parties; uncertainties related to general economic, political, business, industry, regulatory and market conditions; and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls and withdrawals and other unusual items.

Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Media Inquiries

Email: [e-mail]

Phone: [phone]

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAMJBMTMBTMBFF

(END) Dow Jones Newswires

October 03, 2016 09:00 ET (13:00 GMT)